Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 3/20 | 0.37 |
| ▸ | ACE | P12821 | 3/20 | 0.37 |
| ▸ | CPA1 | P15085 | 3/20 | 0.37 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CPA3 | P15088 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | ANPEP | P15144 | 2/20 | 0.34 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17250619 | 1.00 | MME (0.37) | MMEACECPA1ACE2TDP1 | |
| SCHEMBL19008581 | 0.99 | MME (0.38) | MMEACECPA1ACE2TDP1 | |
| SCHEMBL19018034 | 0.90 | MME (0.37) | MMETDP1CYP1A2CPA3FOLH1 | |
| SCHEMBL17250639 | 0.90 | MME (0.37) | MMETDP1CYP1A2CPA3FOLH1 | |
| SCHEMBL19018283 | 0.88 | ACE (0.33) | MMEACECPA1ACE2TDP1 | |
| SCHEMBL17250865 | 0.87 | MME (0.38) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL19018040 | 0.87 | MME (0.38) | MMEACECPA1ACE2ALDH1A1 | |
| SCHEMBL19018256 | 0.85 | BCL2L1 (0.36) | — | |
| SCHEMBL17250494 | 0.85 | BCL2L1 (0.36) | — | |
| SCHEMBL17250493 | 0.84 | JAK3 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9839642-B2 | Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170173035-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173035-A1 | BETA-TETRAZOLYL-PROPIONIC ACIDS AS METALLO-BETA-LACTAMASE INHIBITORS | MGAM, CMBL, PEPD | MME 257/4885ACE 88/4885CPA1 803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.